MAGEC2 (MAGE Family Member C2)

News alerts, weekly reports and conference planners

4ms

Gender- and Grade-Dependent Activation of Androgen Receptor Signaling in Adult-Type Diffuse Gliomas: Epigenetic Insights from a Retrospective Cohort Study. (PubMed, Biomedicines)

Additionally, methylation patterns of AR co-regulators located on the X chromosome suggest epigenetic regulation of AR signaling in gliomas. The findings reveal distinct AR pathway activation patterns in adult-type diffuse gliomas, particularly IDH-wildtype GBMs, suggesting that further exploration of antiandrogen therapies is warranted.

4 months ago

Retrospective data • Journal

MAGEC1 (MAGE Family Member C1) • MAGEA1 (MAGE Family Member A1) • MAGEC2 (MAGE Family Member C2)

AR positive • IDH wild-type

Xtandi (enzalutamide)

9ms

Vaccination with synthetic long peptide and CpG 2395 in AddaVax induces potent anti-tumor effects. (PubMed, Exp Biol Med (Maywood))

This vaccine formulation also conferred protection against challenge with HCA587-expressing B16 melanoma presented by delayed tumor growth and prolonged survival compared. This formulation of HCA587 SLP vaccine holds promise for the treatment of patients with cancer in future clinical trials.

9 months ago

Journal

CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • IFNA1 (Interferon Alpha 1) • MAGEC2 (MAGE Family Member C2)

over1year

A necroptosis-regulated model from single-cell analysis that predicts survival and identifies the Pivotal role of MAGEA6 in hepatocellular carcinoma. (PubMed, Heliyon)

This study successfully developed a six-gene necroptosis-related signature to predict prognoses in HCC patients. It further explored the roles of necroptosis in hepatoma cells and the tumor microenvironment.

over 1 year ago

Journal • IO biomarker

AKR1B10 (Aldo-Keto Reductase Family 1 Member B10) • MAGEA6 (MAGE Family Member A6) • MAGEC2 (MAGE Family Member C2) • SOX4 (SRY-Box Transcription Factor 4)

2years

Application of the iPLUS non-coding sequence in improving biopharmaceuticals production. (PubMed, Front Bioeng Biotechnol)

By incorporating iPLUS in a vector to express a monoclonal antibody used in immunotherapy, in a mammalian cell line used by the industry (ExpiCHO), trastuzumab production increases by 2-fold...Taken together, our study provides data (TLR4) showing that iPLUS may be used as a valuable asset in a variety of systems used by the biotech and biopharmaceutical industry. Our results underscore the critical role of non-coding sequences in controlling gene expression, offering a promising avenue to accelerate, enhance, and cost-effectively optimize biopharmaceutical production processes.

2 years ago

Journal • IO biomarker

TLR4 (Toll Like Receptor 4) • MAGEC2 (MAGE Family Member C2)

Herceptin (trastuzumab)

over2years

Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer. (PubMed, Mol Oncol)

The current study provides a comprehensive evaluation of CTAs, and suggests that their association with immune cells may indicate in situ immunogenic effects. The findings support the rationale to harness CTAs as targets for immunotherapy.

over 2 years ago

Journal • IO biomarker

CD163 (CD163 Molecule) • MAGEA4 (Melanoma antigen family A, 4) • PRAME (Preferentially Expressed Antigen In Melanoma) • FOXP3 (Forkhead Box P3) • MAGEB2 (MAGE Family Member B2) • MAGEC2 (MAGE Family Member C2)

MAGEA4 expression • MAGEA4 overexpression • FOXP3 expression

almost3years

cfDNA methylation in liquid biopsies as potential testicular seminoma biomarker. (PubMed, Epigenomics)

In an analysis of panels of statistically significant CpGs, two DNA methylation panels emerged as potential seminoma screening panels, one in blood CpG8/CpG9/CpG10 (KITLG) and the other in seminal plasma CpG1(MAGEC2)/CpG1(OCT3/4). The presented data promote the development of liquid biopsy epigenetic biomarkers in the screening of seminoma patients.

almost 3 years ago

Journal • Liquid biopsy • Biopsy

MAGEC2 (MAGE Family Member C2)

almost3years

Novel diagnostic biomarkers of T cell-mediated tumor killing characteristics for early-stage triple negative breast cancer: A SEER analysis and molecular portraits. (PubMed, Medicine (Baltimore))

The L-TNBC exhibited a lower rate of survival than E-TNBC, and the 2 groups differed in terms of transcriptome characteristics. To date, the diagnostic value of T cell-mediated tumor killing portraits on E-TNBC may not be completely recognized.

almost 3 years ago

Journal

CTAG1B (Cancer/testis antigen 1B) • TP63 (Tumor protein 63) • MAGEC2 (MAGE Family Member C2) • TNFRSF11B (Tumor necrosis factor receptor superfamily member 11B)

3years

Gene Expression Profile as a Therapeutic Biomarker for Classic Hodgkin Lymphoma Treated with Immunotherapy-Based Regimens (USCAP 2023)

Background : PD-1 blockade treatment with nivolumab is effective in relapsed/refractory Classic Hodgkin Lymphoma (CHL)... IL13 and IL15 modulation may be a logical objective for future therapeutic strategies since their role in proliferation of HL-derived cell-lines in addition to JAK-STAT and MAPK signaling activation. Likewise, SOCS3 for its suppressive role in JAK-STAT pathway. Other dysregulated genes in our series with potential therapeutic targets should be SMAD7, FADD, NFKB1, and MAPK11due to their involvement in variety of process including cell growth and differentiation, apoptosis as well as immune response .

3 years ago

PD(L)-1 Biomarker • Gene Expression Profile • IO biomarker

MAP2K1 (Mitogen-activated protein kinase kinase 1) • CCND1 (Cyclin D1) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • IL2 (Interleukin 2) • IL7R (Interleukin 7 Receptor) • S100A8 (S100 Calcium Binding Protein A8) • FADD (Fas associated via death domain) • MAPK1 (Mitogen-activated protein kinase 1) • ROR2 (Receptor Tyrosine Kinase Like Orphan Receptor 2) • S100A9 (S100 Calcium Binding Protein A9) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • CCL2 (Chemokine (C-C motif) ligand 2) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • TNFRSF4 (TNF Receptor Superfamily Member 4) • IL1A (Interleukin 1, alpha) • IL32 (Interleukin 32) • MLANA (Melan-A) • BAG4 (BAG Cochaperone 4) • CCL22 (C-C Motif Chemokine Ligand 22) • CDC20 (Cell Division Cycle 20) • CTSL (Cathepsin L) • ERCC6 (Excision repair cross-complementation group 6) • IL13 (Interleukin 13) • IL15 (Interleukin 15) • IL22 (Interleukin 22) • SMAD7 (SMAD Family Member 7) • ST6GAL1 (ST6 Beta-Galactoside Alpha-2,6-Sialyltransferase 1) • CD80 (CD80 Molecule) • CDCA8 (Cell Division Cycle Associated 8) • CDK3 (Cyclin Dependent Kinase 3) • CENPA (Centromere protein A) • HNF1A (HNF1 Homeobox A) • IFNL3 (Interferon Lambda 3) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1) • KIF4A (Kinesin Family Member 4A) • KLRB1 (Killer Cell Lectin Like Receptor B1) • LGALS9 (Galectin 9) • MAGEA1 (MAGE Family Member A1) • MAGEC2 (MAGE Family Member C2) • MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4) • MAPK11 (Mitogen-Activated Protein Kinase 11) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA) • PATZ1 (POZ/BTB And AT Hook Containing Zinc Finger 1) • PDHA1 (Pyruvate Dehydrogenase E1 Subunit Alpha 1) • POU2AF1 (POU Class 2 Homeobox Associating Factor 1) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • SOCS3 (Suppressor Of Cytokine Signaling 3) • TGFBR1 (Transforming Growth Factor Beta Receptor 1) • TGIF2 (TGFB Induced Factor Homeobox 2)

HTG EdgeSeq Precision Immuno-Oncology Panel

Opdivo (nivolumab)